ArticleInvestigative ophthalmology & visual science2000
Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.
Article in Investigative ophthalmology & visual science, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 82 citations in OpenAlex.
- Vitreoretinal Myeloid Cell Heterogeneity: Diverse Roles in Homeostasis, Immune Surveillance, and Pathophysiology.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- The Immunobiology of Dry Eye Disease: A Review of the Pathogenesis, Regulation and Therapeutic Implications.International journal of molecular sciences · 2025Review
- The anterior chamber of the eye technology and its anatomical, optical, and immunological bases.Physiological reviews · 2024Review
- Complement regulation in the eye: implications for age-related macular degeneration.The Journal of clinical investigation · 2024Review
- Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis.Advanced drug delivery reviews · 2023Review
- Differential and Altered Spatial Distribution of Complement Expression in Age-Related Macular Degeneration.Investigative ophthalmology & visual science · 2021Article
- Corneal xenotransplantation: Where are we standing?Progress in retinal and eye research · 2021Review
- Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors.International journal of molecular sciences · 2020Review
- Local Activation of the Alternative Pathway of Complement System in Mycotic Keratitis Patient Tear.Frontiers in cellular and infection microbiology · 2020Article
- Transcriptional Profiling Uncovers Human Hyalocytes as a Unique Innate Immune Cell Population.Frontiers in immunology · 2020Article
- Differential Effects of C1qa Ablation on Glaucomatous Damage in Two Sexes in DBA/2NNia Mice.PloS one · 2015Article
- Complement regulatory protein CD46 protects against choroidal neovascularization in mice.The American journal of pathology · 2014Article
- Proliferative vitreoretinopathy may be a risk factor in combined macular hole retinal detachment cases.Retina (Philadelphia, Pa.) · 2013Article
- Retinal changes precede visual dysfunction in the complement factor H knockout mouse.PloS one · 2013Article
- Galectin-9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts.PloS one · 2013Article
- Article
- Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism?Frontiers in immunology · 2012Article
- A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.PloS one · 2011Article
- A caveat for T cell transfer studies: generation of cytotoxic anti-Thy1.2 antibodies in Thy1.1 congenic mice given Thy1.2+ tumors or T cells.Journal of leukocyte biology · 2011Article
- Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice.The Journal of biological chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo identify the molecules in normal human intraocular fluid (aqueous humor and vitreous) that inhibit the functional activity of the complement system.
methodsAqueous humor and vitreous were obtained from patients with noninflammatory ocular disease at the time of surgery. Samples were incubated with normal human serum (NHS), and the mixture assayed for inhibition of the classical and alternative complement pathways using standard CH(50) and AH(50) hemolytic assays, respectively. Both aqueous humor and vitreous were fractionated by microconcentrators and size exclusion column chromatography. The inhibitory molecules were identified by immunoblotting as well as by studying the effect of depletion of membrane cofactor protein (MCP), decay-accelerating factor (DAF), and CD59 on inhibitory activity.
resultsBoth aqueous humor and vitreous inhibited the activity of the classical pathway (CH(50)). Microcentrifugation revealed the major inhibitory activity resided in the fraction with an M(r) >/= 3 kDa. Chromatography on an S-100-HR column demonstrated that the most potent inhibition was associated with the high-molecular-weight fractions (>/=19.5 kDa). In contrast to unfractionated aqueous and vitreous, fractions with an M(r) >/= 3 kDa also had an inhibitory effect on the alternative pathway activity (AH(50)). The complement regulatory activity in normal human intraocular fluid was partially blocked by monoclonal antibodies against MCP, DAF, and CD59. Immunoblot analysis confirmed the presence of these three molecules in normal intraocular fluid.
conclusionsOur results demonstrate that normal human intraocular fluid (aqueous humor and vitreous) contains complement inhibitory factors. Furthermore, the high-molecular-weight factors appear to be the soluble forms of MCP, DAF, and CD59.
Indexed as
Identifiers
11095615PMC1821086W2100969164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.